Sosipatros Alexander Boikos, MD| Hematology Oncology | MedStar Health

Sosipatros Alexander Boikos, MD
Provider is directly employed by MedStar Health

Specialities: Hematology Oncology

Languages: English

202-444-9429

About me

Sosipatros Boikos, MD, is a fellowship-trained, board-certified medical oncologist with clinical privileges at MedStar Washington Hospital Center and MedStar Georgetown University Hospital. He is one of the most experienced sarcoma medical oncologists in the Washington, D.C. metropolitan area, with 11 years of experience treating sarcomas and rare tumors and more than 20 years of experience in the area of sarcoma cancer genetics and cell biology. Dr. Boikos currently serves MedStar Health as Co-Leader of the Sarcoma Working Group at Georgetown Lombardi Comprehensive Cancer Center.  

Dr. Boikos has special training and a clinical interest in treating bone and soft tissue sarcomas; gastrointestinal stromal tumors, including succinate dehydrogenase (SDH) deficient GISTs; and other rare cancers, including adrenocortical carcinomas, paragangliomas, and neuroendocrine tumors. His extensive research expertise lies in the field of precision medicine, cancer genetics, oncometabolomics, and clinical trials.

Prior to joining MedStar Washington and Georgetown Lombardi Comprehensive Cancer Center, Dr. Boikos was an associate professor at the NCI designated Massey Cancer Center/Virginia Commonwealth University, where he served as Director of the Sarcoma Working Group, Co-Director for the Molecular Tumor Board, and Assistant Director of Precision Medicine for the Massey Cancer Center/Virginia Commonwealth University.

Dr. Boikos obtained his medical degree from the University of Crete (Faculty of Medicine) in Greece in 2002. After finishing an internship at Johns Radcliffe Hospital at Oxford University (UK), he joined the National Institutes of Health (USA) in 2004 as a Visiting Research Fellow to study the genetics of gastrointestinal stromal tumors and other rare tumors under Dr. Constantine Stratakis. Dr. Boikos then completed an internal medicine residency at Montefiore Medical Center/ Albert Einstein College of Medicine in New York, followed by a fellowship in medical oncology at the Johns Hopkins University School of Medicine, in Baltimore. 

In 2013, he returned to NIH to coordinate the Pediatric and Wild Type GIST clinic and to lead efforts to further elucidate the genetic and epigenetic alterations in SDH-Deficient tumors. More recent work was focused on developing, in collaboration with Anthony Faber’s laboratory, targeted treatments for early phase clinical testing in sarcomas and other types of rare cancers, with a primary focus on apoptosis. Dr. Boikos and his team were able to demonstrate recently that BCL-2 BH3 mimetics can have significant activity in Ewing Sarcoma and Synovial Sarcoma.

Dr. Boikos has published over 65 peer-reviewed manuscripts in high-impact journals, including Nature Genetics, New England Journal of Medicine, JAMA Oncology, Science Translational Medicine, Journal of Clinical Oncology, and Proceedings of the National Academy of Science. Find a complete list of Dr. Boikos’s published peer-reviewed papers here.

As a highly accomplished physician-scientist who is dedicated to expanding the knowledge of sarcomas and rare tumors, Dr. Boikos has received multiple awards and research funding throughout his career. He has given more than 100 research presentations in both national and international meeting; written several high-impact reviews and book chapters; been a peer reviewer for more than 20 peer-reviewed journals, including Clinical Cancer Research and Endocrine-Related Cancer; and has been an invited lecturer in areas of both his clinical and research interests.

Passionate about educating clinicians in training, Dr. Boikos has mentored several fellows, residents, and MD and MD/PhD students in medical oncology and cancer biology. He is a co-director for the annual MedStar Georgetown Gastric and Soft Tissue Neoplasms Symposiums. Dr. Boikos is a member of several prestigious cancer societies, including the American Society of Clinical Oncology, the European Society of Medical Oncology, the American Academy of Clinical Research, the American College of Physicians, the Southwest Oncology Group, and Sarcoma Alliance for Research through Collaboration. He is also a member of the annual Pediatric and Wild Type GIST Clinic at the National Institutes of Health, the Pediatric & SDH-Deficient GIST Symposium in the US, and the CARIS Sarcoma Precision Medicine Group.

Dr. Boikos is married to Dr. Stamatina Danielides, a rheumatologist in Northern Virginia, and has 3 children; Danae, Ioannis, and Phoebe. When not working, he enjoys sailing, hiking, reading books, listening to music, visiting museums, and traveling with his family.

Philosophy of Care

“My philosophy of care revolves around the Latin phrase, Cura Personalis, which translates to ‘care for the entire person.’

“Sarcoma is a challenging type of cancer that needs a multidisciplinary approach involving many specialists, including medical oncologists, surgical oncologists, radiation oncologists, and other disciplines. My goal is not to treat the diagnosis, but instead the whole person, trying to minimize suffering and help my patients maintain a sense of normalcy in their lives.

“When forming the best evidence-based treatment plan for my patients, I collaborate with sarcoma experts, both nationally and internationally, and consult the literature for treatment breakthroughs and clinical trials.

“I encourage open lines of communication so that my patients approach me with all of their questions and concerns. I feel honored when my patients truly feel that we are on the same team–together in this fight. We are not in a race, but a marathon, and I am with them every step of the way.”

Clinical areas of focus

  • Adrenal Neoplasm
  • Bone Sarcoma
  • Endocrine Carcinoma
  • Ewings Sarcoma
  • Gastrointestinal (GI) Stromal Tumors
  • Osteosarcoma
  • Paraganglioma
  • Pheochromocytoma
  • Sarcoma
  • Synovial Sarcoma
  • Uterine Sarcoma
Show More

Conditions and procedures

Conditions I treat

  • Adrenal Neoplasm
  • Alveolar Rhabdomyosarcoma
  • Alveolar Soft Part Sarcoma
  • Angiomyxoma
  • Angiosarcoma
  • Bone Sarcoma
  • Cardiac Sarcoma
  • Chondrosarcoma
  • Clear Cell Chondrosarcoma
  • Clear Cell Sarcoma
  • Dedifferentiated Liposarcoma
  • Dendritic Cell Sarcoma
  • Dermatofibrosarcoma Protruberans
  • Desmoid Tumors
  • Desmoplastic Small Cell Tumor
  • Desmoplastic Small Round Cell Tumors
  • Endocrine Carcinoma
  • Endometrial Sarcoma
  • Endovascular Papillary Angioendothelioma
  • Epithelioid Hemangioendothelioma
  • Epithelioid Sarcoma
  • Ewings Sarcoma
  • Extrarenal Rhabdoid Tumor
  • Extraskeletal Mesenchymal Chondrosarcoma
  • Extraskeletal Myxoid Chondrosarcoma
  • Extraskeletal Osteosarcoma
  • Fibrosarcoma
  • Fibrosarcoma Of The Head & Neck
  • Gastrointestinal (GI) Stromal Tumors
  • Granulation Cell Sarcoma
  • Hemangioendothelioma
  • Hemangiopericytoma
  • Intimal Sarcoma
  • Kaposi Sarcoma
  • Leiomyosarcoma
  • Leiomyosarcoma Of Uterus
  • Liposarcoma
  • Low Grade Fibromyxoid Sarcoma
  • Lymphangiosarcoma
  • Malignant Fibrous Histiocytoma (MFH)
  • Malignant Glomus Tumor
  • Malignant Granular Cell Tumor
  • Malignant Peripheral Nerve Sheath Tumor
  • Malignant Primitive Neuroectodermal Tumor (PNET)
  • Malignant Schwannoma
  • Malignant Tenosynovial Giant Cell Tumor
  • Myoepithelioma/Mixed Tumor Of Soft Tissue
  • Myofibroblastic Sarcoma
  • Myxofibrosarcoma
  • Myxoinflammatory Fibroblastic Sarcoma
  • Neuroectodermal Tumor
  • Neuroendocrine Tumors
  • Neurofibrosarcoma
  • Osteosarcoma
  • Paraganglioma
  • Parosteal Osteosarcoma
  • Pecoma
  • Pheochromocytoma
  • Pleomorphic Liposarcoma
  • Retroperitoneal Liposarcoma
  • Rhabdomyosarcoma
  • Sarcoma
  • Solitary Fibrous Tumor
  • Spindle Cell Sarcoma
  • Synovial Sarcoma
  • Undifferentiated Pleomorphic Sarcoma
  • Uterine Sarcoma
  • Well Differentiated Liposarcoma
Show All Show Less

Procedures I perform

  • Adjuvant Chemotherapy
  • Biological Targeted Therapy
  • Cancer Chemotherapy
  • Cancer Genomics
  • Cancer Immunotherapy
  • Chemoradiation
  • Early Detection Of Cancer
  • Sarcoma Genomics
Show All button Press enter to expand Show Less

Practice locations

Distance from Change LocationEnter your Location

3800 Reservoir Road Northwest
Washington, DC, 20007

202-444-3111

Fax 202-444-3119

Get Directions

miles away

Fax 202-444-3119

110 Irving Street Northwest
Suite C2149
Washington, DC, 20010

202-877-6998

Fax 202-877-8910

Get Directions

miles away

Fax 202-877-8910

Insurance

MedStar Medical Group accepts most major health insurance plans. If you are uncertain as to whether your individual health insurance plan is accepted at MedStar Medical Group, please call your insurance company.

  • List of insurance plans we accept
    • Mamsi Life & Health (Indem./PPO)
    • OneNet PPO, Inc.
    • Optimum Choice Preferred (POS) & OCI Direct (HMO)
    • M.D. IPA Preferred (POS)
    • M.D. IPA (HMO)
    • United Student Resources
    • United Healthcare Options (PPO) (includes Empire PPO, GEHA, Compass Rose)
    • United Healthcare Choice Plus
    • United Healthcare Select Plus (POS)
    • United Healthcare Select HMO - EPO/NPP
    • United Healthcare Core Essential (HMO)
    • United Healthcare Choice
    • United Healthcare Compass (HMO)
    • United Healthcare Navigate
    • Optimum Choice
    • Tricare for Life (Medicare Supplemental Plan)
    • Tricare Extra (Indemnity)
    • Tricare Standard
    • Tricare Prime
    • Private Health Care Systems (PHCS) (PPO)
    • MedStar Select (MedStar Associates' Plan)
    • MedStar Medicare Choice
    • MedStar Family Choice - Maryland Health Choice
    • FIRST HEALTH
    • Coventry Health Care National Network PPO
    • First Health PPO
    • Coventry of Delaware HMO/PPO
    • Coventry Health Care of Virginia
    • CIGNA Indemnity
    • Great-West Healthcare POS/CIGNA
    • CIGNA POS/Network POS
    • CIGNA HMO & Network (HMO)
    • POS OA & OA Plus
    • Network OA
    • CIGNA HMO Open Access (OA)
    • Choice Fund PPO
    • PPO and PPO Plus
    • CIGNA EPO
    • CFBCBS (NCA) Indemnity
    • CFBCBS Maryland Indemnity or PPO
    • HealthyBlue PPO
    • CFBSBC Blue Preferred PPO
    • CFBCBS Federal Employee Program (Std. & Basic PPO)
    • CFBCBS Maryland Point of Service Plan (MPOS)
    • CFBCBS Blue Choice Opt Out Plus Open Access (POS)
    • CFBCBS BlueChoice HMO
    • Blue Choice Advantage & Healthy Blue (HMO, POS)
    • BlueChoice Open Access
    • CFBCBS Blue Choice Opt Out Open Access
    • Aetna Worker's Compensation Network
    • Aetna Medicare Advantage HMO & PPO Plans
    • Innovation Health: Indemnity
    • Aetna Traditional Choice (PPO)
    • Innovation Health: PPO
    • Aetna Open Choice (PPO)
    • Aetna Student Health Insurance
    • Innovation Health: POS Plus
    • Aetna Managed Choice (POS)
    • Innovation Health: Open Network Only Plus
    • Aetna Elect Choice/ Open Access (POS)
    • Aetna USAccess (POS)
    • Aetna Quality Point of Service (POS)
    • Aetna Elect Choice/ EPO (Aetna Health Fund) Innovation Health: Network Only Plus
    • Open EPO Plus
    • Opoen HMO Option
    • Open HMO
    • Innovation Health: POS
    • Aetna HMO-Open Access/Select OA/HealthFund/Health Network Option OA
    • Open POS II
    • Innovation Health: Open POS Plus
    • Choice POS & Choice POS II
    • Aetna Managed Choice Open Access (POS)
    • Aetna Innovations: HMO & EPO Plus
    • Select HMO/HealthFund/Health Network
    • Aetna HMO

Education

Fellowship Program: Johns Hopkins Hospital (2014)

Residency Program: Montefiore Medical Center (2011)

Fellowship Program: National Institutes of Health (2008)

Medical School: University of Crete School of Medicine (2002)

Medical School: Democritus University of Thrace (1998)

News and publications

Selected Publications in PEER Reviewed Journals:

  • C. Kent Fairchild, Sheeba Jacob, Gregory Domson, Steven C. Smith, Madhavi Puchalapalli, Bin Hu, Anthony C. Faber, Sosipatros A. Boikos The MCL-1 inhibitor S63845 unmasks BCL-2 addiction in synovial sarcoma Cancers (Basel). 2021 May 12;13(10):2310. doi: 10.3390/cancers13102310. Cited in Pubmed :PMID: 33483374

  • Alexander Allen, Steven Smith, Sosipatros Boikos, Benjamin Medalion, John Grizzard, Anthony Cassano, Timothy Harris Pulmonary Artery Intimal Sarcoma Treated with Neoadjuvant Radiation Prior to Pulmonary Artery Endarterectomy Respiratory Cases Medicine Reports . 2021 Apr 27;33:101414.doi: 10.1016/j.rmcr.2021.101414. eCollection 2021. Cited in Pubmed :PMID: 34401262

  • Daniel Heisey, Timothy Lochmann, Marissa Calbert, Maninderjit Ghotra, Yuki Kato Maves, Sosipatros Boikos, Cyril Benes, and Anthony Faber Pharmaceutical interference of the EWS-FLI1-driven transcriptome by co-targeting H3K27ac and RNA polymerase activity in Ewing Sarcoma Molecular Cancer Therapy . 2021 Oct;20(10):1868-1879. doi: 10.1158/1535-7163.MCT-20-0489. Epub 2021 Jul 26. Cited in Pubmed :PMID: 34315769

  • Berg SH, Massoud CM, Jackson-Cook C, Boikos SA, Smith SC, Mochel MC.  A Reappraisal of Superficial Pleomorphic Liposarcoma. American Journal of Clinical Pathology. 2020 Aug 5;154(3):353-361. doi: 10.1093/ajcp/aqaa045. Cited in Pubmed : PMID: 32525520

  • Heisey DAR, Lochmann TL, Floros KV, Coon CM, Powell KM, Jacob S, Calbert ML, Ghotra MS, Stein GT, Kato Maves Y, Smith SC, Benes CH, Leverson JD, Souers AJ, Boikos SA, Faber AC. Ewing’s Sarcoma rely on BCL-2 and BCL-xL to escape PARP inhibitor toxicity Clinical Cancer Research Clin Cancer Res. 2018 Oct 22. Cited in Pubmed : PMID: 30348635

  • Lin Mei, Steven C. Smith, Anthony C. Faber, Jonathan Trent, Steven R. Grossman, Constantine A. Stratakis, Sosipatros A. Boikos Gastrointestinal Stromal Tumors: The GIST of Precision Medicine Trends In Cancer 2018 Jan;4(1):74-91. Cited in Pubmed : PMID: 29413424

  • Priya Gopie, Lin Mei, Anthony Faber, Steven Grossman, Steven Smith, Sosipatros Boikos Classification of Gastrointestinal Stromal Tumor Syndromes Endocrine Related Cancer 2018 Feb;25(2):R49-R58. Cited in Pubmed :PMID: 29170162

  • Lin Mei, Sosipatros Boikos Treatment Challenges in Gastrointestinal Stroma Tumors Frontiers In Oncology Front Oncol. 2018 May 7;8:135. Cited in Pubmed PMID: 29868467

  • Boikos SA*, Pappo AS*, Killian K, Laquaglia MP, Weldon C, George S, Trent JC, Wright J, Schiffman JD, Raygada M, Pacak K, Stratakis C, Meltzer P, Miettinen, M, Janeway KA**, Helman LJ**  Characterization of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report from the NIH GIST Clinic JAMA Oncology 2016 Mar 24. : Cited in Pubmed: PMID 27011036

  • Weldon CB, Madenci AL, Boikos SA, Janeway KA, George S, von Mehren M, Pappo AS, Schiffman JD, Wright J, Trent JC, Pacak K, Stratakis CA, Helman LJ, La Quaglia MP. Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. Journal of Clinical Oncology 2016  J Clin Oncol. 2016 Dec 28 : Cited in Pubmed: PMID 28029307

  • Sosipatros Boikos*, Paraskevi Xekouki*, Fabio Faucz, Karel Pacak, Margarita Raygada, Karen Adams, Eva Szarek, Evan Ball, Su Young Kim, Elena Fumagalli, Markku Miettinen, Lee J. Helman, J. Aidan Carney & Constantine A. Stratakis Few Carney’s Triad patients do have mutations in subunits of the succinate dehydrogenase enzyme. European Journal of Human Genetics Cited in Pubmed: PMID 26173966

  • Forde PM, Cochran R, Boikos SA, Meyer CF, Thornton KA, Montgomery EA, Donehower RC, Park BH familial Gastrointestinal Stromal Tumor Syndrome associated with Loss of Heterozygosity and Amplification of the Mutant KIT Allele. Journal of Clinical Oncology J Clin Oncol. 2016 May 27. Cited in Pubmed: PMID: 24868028

  • Boikos, SA, Helman, LJ, Stratakis, CA, Pediatric and Wildtype GIST Clinic at the National Institutes of Health Thyroid Function in SDH Deficient GIST The New England Journal of Medicine 2014 Jul 3;371(1):85-6. Cited in Pubmed: PMID: 24988575

  • Killian JK, Miettinen M, Walker RL, Wang Y, Zhu YJ, Waterfall JJ, Noyes N, Retnakumar P, Yang Z, Smith WI Jr, Killian MS, Lau CC, Pineda M, Walling J, Stevenson H, Smith C, Wang Z, Lasota J, Kim SY, Boikos SA, Helman LJ, Meltzer PS. Recurrent epimutation of SDHS in gastrointestinal stromal tumors SCIENCE Translational Medicine 2014 Dec 24;6(268):268ra177. Cited in Pubmed: PMID: 25540324

  • Boikos SA & Stratakis CA The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations. Endocrine. 2014 Nov;47(2):401-8. Cited in Pubmed: PMID: 25027296

  • Tsang K, Starost MF, Nesterova M, Boikos SA, Watkins T, Almeida MQ, Harran M, Li A,. Collins M, Cheadle C, Mertz E, Leikin S, Kirschner 7, Robey LS & Stratakis CA Alternate PKA activity identifies a unique population of stromal cells in adult bone. Proceedings of American Academy of Science  2010;107(19):8683-8. Cited in PubMed;  PMID: 20421483

  • Almeida MQ, Muchow M, Boikos S, Bauer AJ, Griffin KJ, Tsang KM, Cheadle C, Watkins T, Wen F, Starost MF, Bossis I, Nesterova M, Stratakis CA. Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/- or Rb1+/- backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling. Human Molecular Genetics  2010; 19(8):1387-98. Cited in PubMed; PMID: 20080939

  • Stratakis CA, Boikos SA. Genetics of adrenal tumors associated with Cushing's syndrome: a new classification for bilateral adrenocortical hyperplasias. Nature Endocrinology Reviews  2007 Nov; 3(11): 748-757. Cited in PubMed; PMID: 17955016.

  • Boikos SA, Stratakis CA. Molecular mechanisms of medullary thyroid carcinoma: current approaches in diagnosis and treatment. Histology Histopathology. 2008 Jan; 23(1): 109-116. Cited in PubMed; PMID: 17952863.

  • Pasini B, McWhinney SR, Bei T, Matyakhina L, Stergiopoulos S, Muchow M, Boikos SA, Ferrando B, Pacak K, Assie G, Baudin E, Chompret A, Ellison JW, Briere JJ, Rustin P, Gimenez-Roqueplo AP, Eng C, Carney JA, Stratakis CA. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. European Journal of Human Genetics. 2008 Jan; 16(1): 79-88. Cited in PubMed; PMID: 17667967.

  • Pasini B, Matyakhina L, Bei T, Muchow M, Boikos S, Ferrando B, Carney JA, Stratakis CA. Multiple gastrointestinal stromal and other tumors caused by platelet-derived growth factor receptor alpha gene mutations: a case associated with a germline V561D defect. Journal of Clinical Endocrinology and Metabolism. 2007 Sep; 92(9): 3728-3732. Cited in PubMed; PMID: 17566086.

  • Matyakhina L, Bei TA, McWhinney SR, Pasini B, Cameron S, Gunawan B, Stergiopoulos SG, Boikos S, Muchow M, Dutra A, Pak E, Campo E, Cid MC, Gomez F, Gaillard RC, Assie G, Füzesi L, Baysal BE, Eng C, Carney JA, Stratakis CA. Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. Journal of Clinical Endocrinology and Metabolism. 2007 Aug; 92(8): 2938-2943. Cited in PubMed; PMID: 17535989.

  • Horvath A, Boikos S, Giatzakis C, Robinson-White A, Groussin L, Griffin KJ, Stein E, Levine E, Delimpasi G, Hsiao HP, Keil M, Heyerdahl S, Matyakhina L, Libè R, Fratticci A, Kirschner LS, Cramer K, Gaillard RC, Bertagna X, Carney JA, Bertherat J, Bossis I, Stratakis CA. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nature Genetics. 2006 Jul; 37(7): 794-800. Cited in PubMed; PMID: 16767104

  • Horvath A, Boikos S, Cramer K and Stratakis CA. (2006, May 1). Genomewide analysis of data generated on the Affymetrix 10K Xba 142 arrays for identification of regions with high probability to contain genes responsible for Micronodular (nonpigmented) Adrenocortical Hyperplasia. (Peer Reviewed Online Publication) Nature Protocols. 2006



View a complete list of Dr. Boikos published peer-reviewed papers